<DOC>
	<DOC>NCT00574756</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved medication for the treatment of angina, on heart function by using echocardiography.</brief_summary>
	<brief_title>Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure, Diastolic</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Moderate of severe diastolic dysfunction, E/Ea&gt;12 Preserved systolic function NYHA Class III QTc &gt;450 msec at enrollment Taking medications that prolong QT interval or are potent inhibitors of CYP3A Significant coronary artery disease Severe valvular disease Hepatic disease Severe kidney disease Women of childbearing age Prior serious ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>